Would you give chemotherapy to a post menopausal woman with ER/PR positive HER2 negative breast cancer, T2N1 with 3+ lymph nodes, Ki-67 30% and OncoType RS of 10?
Answer from: Medical Oncologist at Academic Institution
I would not give this postmenopausal woman adjuvant with a recurrence score of 10 based on RxPONDER trial. In that trial women with recurrence scores of 25 or less were randomized to receive chemotherapy + endocrine versus endocrine therapy alone. The Kaplan Meier curves were superimposable. I would...
Answer from: Medical Oncologist at Academic Institution
I think this is a complicated situation that requires a nuanced approach. We know that clinicopathological features are important, independent of Oncotype RS. I would need to consider age (she is postmenopausal, but there is a difference between a 52-year-old and a 75-year-old), grade, tumor size, %...
Comments
Medical Oncologist at Lynn Reg Cancer Center Agree with Dr. @Saundra S. Buys. I'd love to know ...
Medical Oncologist at Northwell Health 3/10 LNs with macroscopic mets and extracapsular e...
Medical Oncologist at Dana-Farber Cancer Institute Dr. @Meekoo Dhar, out of curiosity, why do the Onc...
Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR Maybe repeat Oncotype in post-op sample to reconci...
Medical Oncologist at Breastlink Medical Group This is a scenario where I'm not sure I believe th...
Medical Oncologist at MD Anderson Cancer Center Agree with this. Will re-send Oncotype postop.
Medical Oncologist at New York Cancer & Blood Specialists A follow-up question, on pre-op Oncotype vs post-o...
Answer from: Medical Oncologist at Community Practice
I would not recommend adjuvant chemotherapy for a postmenopausal woman with 1-3 nodes based on RxPONDER. With an Oncotype of 10, this is an endocrine-sensitive tumor that has favorable prognosis and the key is to start endocrine therapy and plan for extended duration, don’t stop at 5 years for...
Comments
Medical Oncologist All of these thoughts are useful insights into a c...
Answer from: Medical Oncologist at Community Practice
While Oncotype DX Recurrence Score (ODX-RS) has prognostic and predictive value regarding adjuvant chemotherapy, recent studies have shown the clinical distinctiveness in BRCA1/2–driven early breast cancers or invasive lobular breast cancers, as well as the age being an important factor. There...
Comments
Medical Oncologist at MedStar Washington Hospital Center, MedStar Georgetown University Hospital Dr. @Copur,
Would a higher Oncotype score change ...
Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty Thank you for the query, Dr. @Munir. If treated wi...
Medical Oncologist at MedStar Washington Hospital Center, MedStar Georgetown University Hospital Thank you Dr. @Copur. Appreciate your input.